

Ming Zhou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10559793/publications.pdf>

Version: 2024-02-01

199
papers

16,184
citations

17440

63
h-index

16650

123
g-index

209
all docs

209
docs citations

209
times ranked

14402
citing authors

#	ARTICLE	IF	CITATIONS
1	The polycomb group protein EZH2 is involved in progression of prostate cancer. <i>Nature</i> , 2002, 419, 624-629.	27.8	2,411
2	The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1469-1489.	3.7	922
3	Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases. <i>Cancer Research</i> , 2004, 64, 9209-9216.	0.9	816
4	Î±-Methylacyl Coenzyme A Racemase as a Tissue Biomarker for Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2002, 287, 1662.	7.4	565
5	Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma. <i>Cancer Research</i> , 2010, 70, 1063-1071.	0.9	394
6	Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study. <i>Lancet Oncology</i> , The, 2020, 21, 222-232.	10.7	364
7	Fibroblast growth factor 2 control of vascular tone. <i>Nature Medicine</i> , 1998, 4, 201-207.	30.7	348
8	Renal Mass Biopsyâ€”A Renaissance?. <i>Journal of Urology</i> , 2008, 179, 20-27.	0.4	344
9	Changes in cerebral cortex size are governed by fibroblast growth factor during embryogenesis. <i>Nature Neuroscience</i> , 1999, 2, 246-253.	14.8	332
10	Alpha-Methylacyl-CoA Racemase. <i>American Journal of Surgical Pathology</i> , 2002, 26, 926-931.	3.7	274
11	<i>TMPRSS2â€“ERG</i> gene fusion prevalence and class are significantly different in prostate cancer of caucasian, africanâ€“american and japanese patients. <i>Prostate</i> , 2011, 71, 489-497.	2.3	239
12	A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. <i>Lancet Oncology</i> , The, 2015, 16, 676-685.	10.7	229
13	A Preoperative Prognostic Nomogram for Solid Enhancing Renal Tumors 7 cm or Less Amenable to Partial Nephrectomy. <i>Journal of Urology</i> , 2007, 178, 429-434.	0.4	226
14	Renal Angiomyolipoma. <i>American Journal of Surgical Pathology</i> , 2009, 33, 289-297.	3.7	216
15	Metastatic Sarcomatoid Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factorâ€“Targeted Therapy. <i>Journal of Clinical Oncology</i> , 2009, 27, 235-241.	1.6	214
16	Renal Epithelioid Angiomyolipoma With Atypia: A Series of 40 Cases With Emphasis on Clinicopathologic Prognostic Indicators of Malignancy. <i>American Journal of Surgical Pathology</i> , 2010, 34, 715-722.	3.7	203
17	Clear Cell Tubulopapillary Renal Cell Carcinoma: A Study of 36 Distinctive Low-grade Epithelial Tumors of the Kidney. <i>American Journal of Surgical Pathology</i> , 2010, 34, 1608-1621.	3.7	185
18	von Hippel-Lindau Gene Status and Response to Vascular Endothelial Growth Factor Targeted Therapy for Metastatic Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2008, 180, 860-866.	0.4	180

#	ARTICLE	IF	CITATIONS
19	Comparison of the Basal Cell-Specific Markers, 34Î²E12 and p63, in the Diagnosis of Prostate Cancer. <i>American Journal of Surgical Pathology</i> , 2002, 26, 1161-1168.	3.7	175
20	Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusionâ€”targeted Prostate Biopsy Outcomes. <i>European Urology</i> , 2016, 69, 512-517.	1.9	163
21	Tubulocystic Carcinoma of the Kidney. <i>American Journal of Surgical Pathology</i> , 2008, 32, 177-187.	3.7	156
22	Expression of Prostate-Specific Membrane Antigen in Tumor-Associated Neovasculature of Renal Neoplasms. <i>Urology</i> , 2007, 70, 385-390.	1.0	147
23	The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 461-493.	2.5	143
24	Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge. <i>Nature Medicine</i> , 2022, 28, 154-163.	30.7	143
25	Basal Cell Cocktail (34Î²E12 + p63) Improves the Detection of Prostate Basal Cells. <i>American Journal of Surgical Pathology</i> , 2003, 27, 365-371.	3.7	141
26	Fibroblast growth factor-2 mediates pressure-induced hypertrophic response. <i>Journal of Clinical Investigation</i> , 1999, 104, 709-719.	8.2	141
27	Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. <i>Urology</i> , 2004, 63, 1138-1142.	1.0	140
28	Eosinophilic, Solid, and Cystic Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2016, 40, 60-71.	3.7	139
29	The Usefulness of Immunohistochemical Markers in the Differential Diagnosis of Renal Neoplasms. <i>Clinics in Laboratory Medicine</i> , 2005, 25, 247-257.	1.4	138
30	New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. <i>Modern Pathology</i> , 2021, 34, 1392-1424.	5.5	138
31	Expression and Diagnostic Utility of Alpha-Methylacyl-CoA-Racemase (P504S) in Foamy Gland and Pseudohyperplastic Prostate Cancer. <i>American Journal of Surgical Pathology</i> , 2003, 27, 772-778.	3.7	128
32	Carcinoma of the Collecting Ducts of Bellini and Renal Medullary Carcinoma. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1265-1278.	3.7	127
33	A Working Group Classification of Focal Prostate Atrophy Lesions. <i>American Journal of Surgical Pathology</i> , 2006, 30, 1281-1291.	3.7	123
34	Î±-Methylacyl-CoA Racemase: Expression Levels of this Novel Cancer Biomarker Depend on Tumor Differentiation. <i>American Journal of Pathology</i> , 2002, 161, 841-848.	3.8	121
35	Renal Tubulocystic Carcinoma Is Closely Related to Papillary Renal Cell Carcinoma: Implications for Pathologic Classification. <i>American Journal of Surgical Pathology</i> , 2009, 33, 1840-1849.	3.7	121
36	Development and Validation of a Deep Learning Algorithm for Gleason Grading of Prostate Cancer From Biopsy Specimens. <i>JAMA Oncology</i> , 2020, 6, 1372.	7.1	119

#	ARTICLE	IF	CITATIONS
37	Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. <i>Modern Pathology</i> , 2021, 34, 1167-1184.	5.5	118
38	How Often Does Alpha-Methylacyl-CoA-Racemase Contribute to Resolving an Atypical Diagnosis on Prostate Needle Biopsy Beyond That Provided by Basal Cell Markers?. <i>American Journal of Surgical Pathology</i> , 2004, 28, 239-243.	3.7	116
39	Cardiac-Specific Overexpression of Fibroblast Growth Factor-2 Protects Against Myocardial Dysfunction and Infarction in a Murine Model of Low-Flow Ischemia. <i>Circulation</i> , 2003, 108, 3140-3148.	1.6	115
40	Best Practices Recommendations in the Application of Immunohistochemistry in the Kidney Tumors. <i>American Journal of Surgical Pathology</i> , 2014, 38, e35-e49.	3.7	110
41	Eosinophilic Solid and Cystic Renal Cell Carcinoma (ESC RCC). <i>American Journal of Surgical Pathology</i> , 2017, 41, 1299-1308.	3.7	107
42	Utility of PTEN and ERG Immunostaining for Distinguishing High-grade PIN From Intraductal Carcinoma of the Prostate on Needle Biopsy. <i>American Journal of Surgical Pathology</i> , 2015, 39, 169-178.	3.7	99
43	BRAF Mutations in Metanephric Adenoma of the Kidney. <i>European Urology</i> , 2012, 62, 917-922.	1.9	95
44	Grading of Clear Cell Renal Cell Carcinoma Should be Based on Nucleolar Prominence. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1134-1139.	3.7	93
45	Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. <i>Modern Pathology</i> , 2009, 22, 1176-1185.	5.5	91
46	ETS Gene Aberrations in Atypical Cribriform Lesions of the Prostate. <i>American Journal of Surgical Pathology</i> , 2010, 34, 478-485.	3.7	91
47	Diagnostic criteria for oncocytic renal neoplasms: a survey of urologic pathologists. <i>Human Pathology</i> , 2017, 63, 149-156.	2.0	89
48	Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy in a Consecutive Cohort of Men with No Previous Biopsy: Reduction of Over Detection through Improved Risk Stratification. <i>Journal of Urology</i> , 2015, 194, 1601-1606.	0.4	87
49	Paraganglioma of the Urinary Bladder. <i>American Journal of Surgical Pathology</i> , 2004, 28, 94-100.	3.7	86
50	Angiomyolipoma with Minimal Fat on MDCT: Can Counts of Negative-Attenuation Pixels Aid Diagnosis?. <i>American Journal of Roentgenology</i> , 2009, 192, 438-443.	2.2	86
51	Adult Cystic Nephroma and Mixed Epithelial and Stromal Tumor of the Kidney Are the Same Disease Entity. <i>American Journal of Surgical Pathology</i> , 2009, 33, 72-80.	3.7	84
52	Artificial intelligence assistance significantly improves Gleason grading of prostate biopsies by pathologists. <i>Modern Pathology</i> , 2021, 34, 660-671.	5.5	84
53	Usefulness of Basal Cell Cocktail (34 β E12 + p63) in the Diagnosis of Atypical Prostate Glandular Proliferations. <i>American Journal of Clinical Pathology</i> , 2004, 122, 517-523.	0.7	82
54	Adult Cystic Nephroma and Mixed Epithelial and Stromal Tumor of the Kidney: Clinical, Radiographic, and Pathologic Characteristics. <i>Urology</i> , 2008, 71, 1142-1148.	1.0	82

#	ARTICLE	IF	CITATIONS
55	Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists. <i>Histopathology</i> , 2016, 69, 441-449.	2.9	82
56	Atypical Cribriform Lesions of the Prostate: Relationship to Prostatic Carcinoma and Implication for Diagnosis in Prostate Biopsies. <i>American Journal of Surgical Pathology</i> , 2010, 34, 470-477.	3.7	80
57	Incidence and clinicopathological characteristics of intraductal carcinoma detected in prostate biopsies: a prospective cohort study. <i>Histopathology</i> , 2013, 63, 574-579.	2.9	80
58	Gleason Score 3+4=7 Prostate Cancer With Minimal Quantity of Gleason Pattern 4 on Needle Biopsy Is Associated With Low-risk Tumor in Radical Prostatectomy Specimen. <i>American Journal of Surgical Pathology</i> , 2014, 38, 1096-1101.	3.7	78
59	ERG gene rearrangement status in prostate cancer detected by immunohistochemistry. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011, 459, 441-447.	2.8	77
60	High-grade prostatic intraepithelial neoplasia, PIN-like carcinoma, ductal carcinoma, and intraductal carcinoma of the prostate. <i>Modern Pathology</i> , 2018, 31, 71-79.	5.5	73
61	Prebiopsy MRI and MRI-ultrasound Fusion-targeted Prostate Biopsy in Men With Previous Negative Biopsies: Impact on Repeat Biopsy Strategies. <i>Urology</i> , 2015, 86, 1192-1199.	1.0	71
62	A Clinicopathologic and Molecular Analysis of Fumarate Hydratase-deficient Renal Cell Carcinoma in 32 Patients. <i>American Journal of Surgical Pathology</i> , 2020, 44, 98-110.	3.7	69
63	Molecular Genetics of Familial Renal Cell Carcinoma Syndromes. <i>Clinics in Laboratory Medicine</i> , 2005, 25, 259-277.	1.4	68
64	The incidence of high-grade prostatic intraepithelial neoplasia and atypical glands suspicious for carcinoma on first-time saturation needle biopsy, and the subsequent risk of cancer. <i>BJU International</i> , 2007, 99, 770-774.	2.5	67
65	The Utility of ERG/P63 Double Immunohistochemical Staining in the Diagnosis of Limited Cancer in Prostate Needle Biopsies. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1062-1068.	3.7	67
66	Diagnosis of "Poorly Formed Glands" Gleason Pattern 4 Prostatic Adenocarcinoma on Needle Biopsy. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1331-1339.	3.7	67
67	Re-evaluating the concept of "dominant/index tumor nodule" in multifocal prostate cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 464, 589-594.	2.8	66
68	Biallelic Alteration and Dysregulation of the Hippo Pathway in Mucinous Tubular and Spindle Cell Carcinoma of the Kidney. <i>Cancer Discovery</i> , 2016, 6, 1258-1266.	9.4	66
69	Mucinous adenocarcinoma of the prostate does not confer poor prognosis. <i>Urology</i> , 2006, 68, 825-830.	1.0	64
70	Renal neuroendocrine tumours: a clinicopathological study. <i>BJU International</i> , 2007, 100, 070907033641008-???	2.5	64
71	Rhabdoid Differentiation Is Associated With Aggressive Behavior in Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2014, 38, 1260-1265.	3.7	61
72	Quantification of Carbonic Anhydrase IX Expression in Serum and Tissue of Renal Cell Carcinoma Patients Using Enzyme-linked Immunosorbent Assay: Prognostic and Diagnostic Potentials. <i>Urology</i> , 2010, 75, 257-261.	1.0	60

#	ARTICLE	IF	CITATIONS
73	The Diagnostic Utility of Novel Immunohistochemical Marker ERG in the Workup of Prostate Biopsies With "Atypical Glands Suspicious for Cancer". American Journal of Surgical Pathology, 2011, 35, 608-614.	3.7	59
74	Neoadjuvant docetaxel treatment for locally advanced prostate cancer. Cancer, 2007, 110, 1248-1254.	4.1	55
75	Intraductal Carcinoma of the Prostate. Archives of Pathology and Laboratory Medicine, 2012, 136, 418-425.	2.5	55
76	Metanephric adenoma and solid variant of papillary renal cell carcinoma: common and distinctive features. Histopathology, 2013, 62, 941-953.	2.9	54
77	Primary Leiomyosarcoma of the Kidney: A Clinicopathologic Study of 27 Cases. American Journal of Surgical Pathology, 2010, 34, 238-242.	3.7	53
78	ERG Protein Expression in Human Tumors Detected With a Rabbit Monoclonal Antibody. American Journal of Clinical Pathology, 2012, 138, 803-810.	0.7	53
79	ERG rearrangement is present in a subset of transition zone prostatic tumors. Modern Pathology, 2010, 23, 1499-1506.	5.5	52
80	Mini-review: perspective of the microbiome in the pathogenesis of urothelial carcinoma. American Journal of Clinical and Experimental Urology, 2014, 2, 57-61.	0.4	52
81	Can Saturation Biopsy Predict Prostate Cancer Localization in Radical Prostatectomy Specimens: A Correlative Study and Implications for Focal Therapy. Urology, 2010, 76, 682-687.	1.0	51
82	QUANTITATIVE GSTP1 METHYLATION LEVELS CORRELATE WITH GLEASON GRADE AND TUMOR VOLUME IN PROSTATE NEEDLE BIOPSIES. Journal of Urology, 2004, 171, 2195-2198.	0.4	48
83	Role of microRNA-27a in down-regulation of angiogenic factor AGGF1 under hypoxia associated with high-grade bladder urothelial carcinoma. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 712-725.	3.8	48
84	Renal mass sampling: An enlightened perspective. International Journal of Urology, 2011, 18, 5-19.	1.0	47
85	Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase α -inhibiting therapy. BJU International, 2010, 106, 62-65.	2.5	46
86	Atypical Cribriform Lesions of the Prostate. Advances in Anatomic Pathology, 2012, 19, 270-278.	4.3	44
87	Diagnosis of Gleason Pattern 5 Prostate Adenocarcinoma on Core Needle Biopsy. American Journal of Surgical Pathology, 2015, 39, 1242-1249.	3.7	43
88	The diagnostic use of ERG in resolving an "atypical glands suspicious for cancer" diagnosis in prostate biopsies beyond that provided by basal cell and β -methylacyl-CoA-racemase markers. Human Pathology, 2013, 44, 786-794.	2.0	42
89	Intracrine and Autocrine Effects of Basic Fibroblast Growth Factor in Vascular Smooth Muscle Cells. Journal of Molecular and Cellular Cardiology, 1997, 29, 1061-1072.	1.9	41
90	Handling and reporting of orchidectomy specimens with testicular cancer: areas of consensus and variation among 25 experts and 225 European pathologists. Histopathology, 2015, 67, 313-324.	2.9	41

#	ARTICLE	IF	CITATIONS
91	Risk Stratification by Urinary Prostate Cancer Gene 3 Testing Before Magnetic Resonance Imaging-Ultrasound Fusion-targeted Prostate Biopsy Among Men With No History of Biopsy. <i>Urology</i> , 2017, 99, 174-179.	1.0	41
92	Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC/MTOR mutations: next-generation sequencing multi-institutional study of 19 cases. <i>Modern Pathology</i> , 2022, 35, 344-351.	5.5	40
93	<scp>WHO</scp> 2022 landscape of papillary and chromophobe renal cell carcinoma. <i>Histopathology</i> , 2022, 81, 426-438.	2.9	39
94	Atypical Intraductal Cribriform Proliferations of the Prostate Exhibit Similar Molecular and Clinicopathologic Characteristics as Intraductal Carcinoma of the Prostate. <i>American Journal of Surgical Pathology</i> , 2017, 41, 550-556.	3.7	38
95	Utility of Pathology Imagebase for standardisation of prostate cancer grading. <i>Histopathology</i> , 2018, 73, 8-18.	2.9	36
96	Enhanced IMP3 Expression Activates NF- κ B Pathway and Promotes Renal Cell Carcinoma Progression. <i>PLoS ONE</i> , 2015, 10, e0124338.	2.5	35
97	Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder. <i>Annals of Diagnostic Pathology</i> , 2015, 19, 301-305.	1.3	35
98	Discrepancy in prostate cancer localization between biopsy and prostatectomy specimens in patients with unilateral positive biopsy: Implications for focal therapy. <i>Prostate</i> , 2012, 72, 1179-1186.	2.3	34
99	VSTM2A Overexpression Is a Sensitive and Specific Biomarker for Mucinous Tubular and Spindle Cell Carcinoma (MTSCC) of the Kidney. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1571-1584.	3.7	34
100	Renal neuroendocrine tumors. <i>Indian Journal of Urology</i> , 2009, 25, 155.	0.6	33
101	Mixed Epithelial and Stromal Tumors of the Kidney. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1114-1122.	3.7	31
102	Differential Expression of Melanocytic Markers in Myoid, Lipomatous, and Vascular Components of Renal Angiomyolipomas. <i>Archives of Pathology and Laboratory Medicine</i> , 2007, 131, 122-125.	2.5	31
103	Microscopic bladder neck involvement by prostate carcinoma in radical prostatectomy specimens is not a significant independent prognostic factor. <i>Modern Pathology</i> , 2009, 22, 385-392.	5.5	29
104	Recent advances in prostate cancer pathology: Gleason grading and beyond. <i>Pathology International</i> , 2016, 66, 260-272.	1.3	28
105	Disruption of tubular Flcn expression as a mouse model for renal tumor induction. <i>Kidney International</i> , 2015, 88, 1057-1069.	5.2	27
106	Features and Prognostic Significance of Intraductal Carcinoma of the Prostate. <i>European Urology Oncology</i> , 2018, 1, 21-28.	5.4	27
107	The Prognostic Significance of Epidermal Growth Factor Receptor Expression in Clear-Cell Renal Cell Carcinoma: A Call for Standardized Methods for Immunohistochemical Evaluation. <i>Clinical Genitourinary Cancer</i> , 2007, 5, 264-270.	1.9	26
108	Do Not Misinterpret Intraductal Carcinoma of the Prostate as High-grade Prostatic Intraepithelial Neoplasia!. <i>European Urology</i> , 2012, 62, 518-522.	1.9	26

#	ARTICLE	IF	CITATIONS
109	Intraductal carcinoma of the prostate: the whole story. <i>Pathology</i> , 2013, 45, 533-539.	0.6	26
110	Gene targeted ablation of high molecular weight fibroblast growth factor α 2. <i>Developmental Dynamics</i> , 2009, 238, 351-357.	1.8	25
111	Clear cell papillary renal cell carcinoma: a review. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 7312-8.	0.5	24
112	The impact of location and number of cores on the diagnostic accuracy of renal mass biopsy: an ex vivo study. <i>World Journal of Urology</i> , 2013, 31, 1159-1164.	2.2	23
113	The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia. <i>Advances in Anatomic Pathology</i> , 2021, 28, 179-195.	4.3	23
114	Localized Cystic Disease of the Kidney. <i>American Journal of Surgical Pathology</i> , 2013, 37, 506-513.	3.7	22
115	Challenges in Pathologic Staging of Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1253-1261.	3.7	22
116	Distinguishing Clear Cell Renal Cell Carcinoma, Retroperitoneal Paraganglioma, and Adrenal Cortical Lesions on Limited Biopsy Material. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2010, 18, 414-421.	1.2	21
117	Pathologic Characteristics of Solitary Small Renal Masses. <i>American Journal of Clinical Pathology</i> , 2008, 130, 560-564.	0.7	20
118	ERG expression in mucinous prostatic adenocarcinoma and prostatic adenocarcinoma with mucinous features: comparison with conventional prostatic adenocarcinoma. <i>Human Pathology</i> , 2013, 44, 2241-2246.	2.0	20
119	Identification of areas of grading difficulties in prostate cancer and comparison with artificial intelligence assisted grading. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 777-786.	2.8	20
120	The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers. <i>Advances in Anatomic Pathology</i> , 2021, 28, 196-208.	4.3	20
121	Expanding the clinicopathological spectrum of succinate dehydrogenase-deficient renal cell carcinoma with a focus on variant morphologies: a study of 62 new tumors in 59 patients. <i>Modern Pathology</i> , 2022, 35, 836-849.	5.5	20
122	Expression of ERG protein, a prostate cancer specific marker, in high grade prostatic intraepithelial neoplasia (HGPIN): lack of utility to stratify cancer risks associated with HGPIN. <i>BJU International</i> , 2012, 110, E751-5.	2.5	19
123	Pathology Imagebase $\text{\textcircled{R}}$ a reference image database for standardization of pathology. <i>Histopathology</i> , 2017, 71, 677-685.	2.9	19
124	Dataset for the reporting of prostate carcinoma in radical prostatectomy specimens: updated recommendations from the International Collaboration on Cancer Reporting. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 263-277.	2.8	19
125	Dataset for the reporting of prostate carcinoma in core needle biopsy and transurethral resection and enucleation specimens: recommendations from the International Collaboration on Cancer Reporting (ICCR). <i>Pathology</i> , 2019, 51, 11-20.	0.6	19
126	Intraductal Carcinoma of Prostate: A Comprehensive and Concise Review. <i>Korean Journal of Pathology</i> , 2013, 47, 307.	1.3	18

#	ARTICLE	IF	CITATIONS
127	The Use of Magnetic Resonance Imaging to Predict Oncological Control Among Candidates for Focal Ablation of Prostate Cancer. <i>Urology</i> , 2018, 112, 121-125.	1.0	18
128	Size-adjusted Quantitative Gleason Score as a Predictor of Biochemical Recurrence after Radical Prostatectomy. <i>European Urology</i> , 2016, 70, 248-253.	1.9	17
129	Intraoperative Consultation and Macroscopic Handling. <i>American Journal of Surgical Pathology</i> , 2018, 42, e33-e43.	3.7	16
130	The reporting of prostate cancer on needle biopsy: prognostic and therapeutic implications and the utility of diagnostic markers. <i>Pathology</i> , 2003, 35, 472-479.	0.6	15
131	Mixed Epithelial and Stromal Tumor of the Kidney. <i>Journal of Urology</i> , 2009, 181, 1879-1880.	0.4	15
132	Single Focus Prostate Cancer: Pathological Features and ERG Fusion Status. <i>Journal of Urology</i> , 2011, 185, 489-494.	0.4	15
133	Number and location of nucleoli and presence of apoptotic bodies in diagnostically challenging cases of prostate adenocarcinoma on needle biopsy. <i>Human Pathology</i> , 2005, 36, 1172-1177.	2.0	14
134	Lymphomas and lymphoproliferative disorders clinically presenting as renal carcinoma: A clinicopathological study of 14 cases. <i>Pathology</i> , 2013, 45, 657-663.	0.6	14
135	Data set for the reporting of carcinoma of renal tubular origin: recommendations from the International Collaboration on Cancer Reporting (<sc>ICCR</sc>). <i>Histopathology</i> , 2019, 74, 377-390.	2.9	14
136	Multiparametric magnetic resonance imaging identifies significant apical prostate cancers. <i>BJU International</i> , 2018, 121, 239-243.	2.5	13
137	Upper tract urinary cytology to detect upper tract urothelial carcinoma: Using the Johns Hopkins Hospital template and evaluation of its feasibility. <i>CytoJournal</i> , 2015, 12, 17.	1.7	13
138	Solid variant of papillary cystadenoma of the epididymis. <i>Histopathology</i> , 2015, 67, 138-141.	2.9	12
139	Modification of the pT2 substage classification in prostate adenocarcinoma. <i>Human Pathology</i> , 2016, 56, 57-63.	2.0	12
140	Prostate Cancers Detected by Magnetic Resonance Imaging—Targeted Biopsies Have a Higher Percentage of Gleason Pattern 4 Component and Are Less Likely to Be Upgraded in Radical Prostatectomies. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 86-91.	2.5	12
141	Clinicopathological features of prostate cancers detected after an initial diagnosis of “atypical glands suspicious for cancer”. <i>Pathology</i> , 2010, 42, 334-338.	0.6	11
142	Molecular Genetic Alterations in Renal Cell Carcinomas With Tubulocystic Pattern: Tubulocystic Renal Cell Carcinoma, Tubulocystic Renal Cell Carcinoma With Heterogenous Component and Familial Leiomyomatosis-associated Renal Cell Carcinoma. <i>Clinicopathologic and Molecular Genetic Analysis of 15 Cases. Applied Immunohistochemistry and Molecular Morphology</i> , 2016, 24, 521-530.	1.2	11
143	Juxtaglomerular Cell Tumor With Atypical Pathological Features: Report of a Case and Review of Literature. <i>International Journal of Surgical Pathology</i> , 2020, 28, 87-91.	0.8	11
144	Clinicopathologic features and outcomes of anterior-dominant prostate cancer: implications for diagnosis and treatment. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 435-440.	3.9	11

#	ARTICLE	IF	CITATIONS
145	Aberrant integrin $\hat{\nu}$ and $\hat{\pm}5$ expression in prostate adenocarcinomas and bone-metastases is consistent with a bone-colonizing phenotype. <i>Translational Andrology and Urology</i> , 2020, 9, 1630-1638.	1.4	10
146	Mucinous tubular and spindle cell carcinoma of the kidney: Diagnosis by fine needle aspiration and review of the literature. <i>CytoJournal</i> , 2015, 12, 28.	1.7	9
147	Urothelial Carcinoma and its Variants. <i>Surgical Pathology Clinics</i> , 2008, 1, 159-209.	1.7	7
148	Analytic Sensitivity of 3 Nucleic Acid Detection Assays in Diagnosis of SARS-CoV-2 Infection. <i>journal of applied laboratory medicine</i> , The, 2021, 6, 421-428.	1.3	7
149	The changing face of renal cell carcinoma pathology. <i>Current Oncology Reports</i> , 2008, 10, 235-244.	4.0	6
150	Prostatic Adenocarcinoma, Prostatic Intraepithelial Neoplasia, and Intraductal Carcinoma. <i>Surgical Pathology Clinics</i> , 2008, 1, 43-75.	1.7	6
151	Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 295.e1-295.e8.	1.6	6
152	Papillary or pseudopapillary tumors of the kidney. <i>Seminars in Diagnostic Pathology</i> , 2015, 32, 124-139.	1.5	5
153	Incidence of intraductal carcinoma, multifocality and bilateral significant disease in radical prostatectomy specimens from Japan and United States. <i>Pathology International</i> , 2016, 66, 672-677.	1.3	5
154	Review of hereditary leiomyomatosis renal cell carcinoma with focus on clinical and pathobiological aspects of renal tumors. <i>Polish Journal of Pathology</i> , 2017, 68, 284-290.	0.3	5
155	Pathology of Renal Cell Carcinoma. , 2013, , 23-41.		4
156	Dataset for the reporting of renal biopsy for tumour: recommendations from the International Collaboration on Cancer Reporting (ICCR). <i>Journal of Clinical Pathology</i> , 2019, 72, 573-578.	2.0	4
157	Diagnosis of "cribriform" prostatic adenocarcinoma: an interobserver reproducibility study among urologic pathologists with recommendations. <i>American Journal of Cancer Research</i> , 2021, 11, 3990-4001.	1.4	4
158	New and emerging renal tumour entities. <i>Diagnostic Histopathology</i> , 2016, 22, 47-56.	0.4	3
159	Localized Renal Masses: Comment on Recent American Urological Association Guideline. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 659-659.	2.5	3
160	Clinical Applications of Immunohistochemistry in Germ Cell Tumors in Men. <i>Methods in Molecular Biology</i> , 2021, 2195, 13-29.	0.9	3
161	Differential diagnosis of renal tumors with tubulopapillary architecture in children and young adults: a case report and review of literature. <i>American Journal of Clinical and Experimental Urology</i> , 2014, 2, 266-72.	0.4	3
162	Bilateral Tubulocystic Renal Cell Carcinomas in Diabetic End-Stage Renal Disease: First Case Report with Cytogenetic and Ultrastructural Studies. <i>Rare Tumors</i> , 2013, 5, 185-188.	0.6	2

#	ARTICLE	IF	CITATIONS
163	Molecular genetics and immunohistochemistry of renal tumours: translation into clinical practice. <i>Diagnostic Histopathology</i> , 2016, 22, 73-79.	0.4	2
164	Pathology of Renal Cell Carcinoma. , 2020, , 49-72.		2
165	Molecular Genitourinary Pathology. , 2009, , 379-392.		2
166	Ureter, Urinary Bladder, and Kidney. , 2010, , 487-538.		1
167	Pathology of Genitourinary Malignancies: Implications for Clinical Management. <i>Seminars in Oncology Nursing</i> , 2012, 28, 143-153.	1.5	1
168	Histologic Variants of Acinar Adenocarcinoma, Ductal Adenocarcinoma, Neuroendocrine Tumors, and Other Carcinomas. , 2019, , 69-95.		1
169	Effect of neoadjuvant docetaxel treatment for locally advanced prostate cancer on miRNA expression: A pilot study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 139-139.	1.6	1
170	Neoplasms of the Prostate and Seminal Vesicles. , 2007, , 56-108.		1
171	Pathology of Renal Cell Carcinoma. , 2013, , 51-69.		1
172	Genetic and Epigenetic Alterations in Renal Cell Carcinoma. , 2015, , 407-415.		1
173	The Utility of Immunohistochemistry in the Differential Diagnosis of Renal Cell Carcinomas. , 2015, , 383-399.		1
174	Molecular Biomarker Testing in Localized Prostate Cancer: The Critical Role of Pathologists. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 264-265.	2.5	1
175	Uncommon Tumors of the Kidney. , 2006, , 1-17.		0
176	Ovarian-type Stroma in Cystic Nephroma. <i>American Journal of Surgical Pathology</i> , 2010, 34, 127.	3.7	0
177	Benign mimickers and potential precursors of prostatic adenocarcinoma. <i>Diagnostic Histopathology</i> , 2011, 17, 434-446.	0.4	0
178	Immunohistochemistry in Prostate Biopsy Evaluation. , 2012, , 29-40.		0
179	Differential Expression Patterns of Chicken Ovalbumin Upstream Promoter-Transcription Factor II (COUPTFII) in Primary Renal Cell Neoplasms. <i>American Journal of Clinical Pathology</i> , 2014, 142, A216-A216.	0.7	0
180	Anatomy and Normal Histology of the Prostate Pertinent to Biopsy Interpretation. , 2019, , 1-10.		0

#	ARTICLE	IF	CITATIONS
181	Reporting of Prostate Biopsy. , 2019, , 185-194.		0
182	Immunohistochemistry in Prostate Biopsy Evaluation. , 2019, , 33-43.		0
183	Contemporary Approach to Gleason Grading of Prostate Cancer. , 2019, , 45-67.		0
184	Benign Mimics of Prostate Carcinoma. , 2019, , 97-125.		0
185	Intraductal Carcinoma of the Prostate (IDC-P) and Atypical Intraductal Proliferation (AIP). , 2019, , 127-132.		0
186	High-Grade Prostatic Intraepithelial Neoplasia. , 2019, , 133-141.		0
187	A high-grade renal cell carcinoma with Somatic BRCA2 mutation. Pathology International, 2019, 69, 432-433.	1.3	0
188	Ureter, Urinary Bladder, and Kidney. , 2022, , 487-564.		0
189	Pathology of Renal Cell Carcinomas. , 2008, , 55-71.		0
190	Benign Mimics of Prostate Carcinoma. , 2012, , 79-113.		0
191	High-Grade Prostatic Intraepithelial Neoplasia. , 2012, , 121-130.		0
192	Atypical Cribriform Lesions of the Prostate Gland: Emerging Concepts of Intraductal Carcinoma of the Prostate (IDC-P). , 2012, , 115-120.		0
193	Reporting of Prostate Biopsy. , 2012, , 173-180.		0
194	Contemporary Approach to Gleason Grading of Prostate Cancer. , 2012, , 41-55.		0
195	Molecular Biology of Prostate Cancer and Emerging Diagnostic and Prognostic Biomarkers. , 2012, , 157-167.		0
196	Histologic Variants of Prostate Carcinoma. , 2012, , 57-78.		0
197	Prostate Pathology. , 2021, , 133-186.		0
198	Prostate basal cell lesions can be negative for basal cell keratins: a diagnostic pitfall. , 2006, 28, 125-9.		0

#	ARTICLE	IF	CITATIONS
199	“Papillary Adenoma-like” Renal Tumor with <i>TFE3</i> Gene Rearrangement, A Potential Precursor to or Early Event in the Development of TFE3 Translocation Renal Cell Carcinoma. International Journal of Surgical Pathology, 0, , 106689692211087.	0.8	0